Rose McNulty

Sheela Rao, MBBS, FRCP, MD, consultant medical oncologist at the Royal Marsden Hospital, discussed the findings of the POD1UM-303/InterAACT2 trial of retifanlimab plus chemotherapy for squamous cell carcinoma of the anal canal (SCAC).

Jonathan Riess, MD, MS, director of thoracic medicine at UC Davis Health, gave insight into the rationale and efficacy data for combining cancer vaccine IO102-IO103 with pembrolizumab in advanced squamous cell carcinoma of the head and neck.

Deepened, persistent responses were seen in the long term among patients with advanced melanoma treated with fianlimab and cemiplimab, Meredith McKean, MD, MPH, director of melanoma and skin cancer research for Sarah Cannon Research Institute, explained.

New prevalence estimates of atrial fibrillation found that approximately 10.5 million US adults, or 5% of the population, have the condition.

The rate of uninsurance in 2023 was 8.0%, a statistically insignificant change from the 7.9% uninsured rate in 2022.

An electronic version of the Symbol-Digit Modalities Test could enable people with multiple sclerosis (MS) to perform frequent remote cognitive assessments independently.

Dax Kurbegov, MD, senior vice president of Sarah Cannon Cancer Network, discussed divides between payers, health systems, and oncology care providers, as well as the impacts these divides can have on patients.

The findings may help inform policy changes at the federal level aiming to address unfair and deceptive pharmacy benefit manager (PBM) practices.

Measurements on a standard phantom and a clinical data set of patients with Duchenne muscular dystrophy (DMD) were used to validate a novel robust reference frequency method approach, which outperformed typical imaging strategies.

Ticiana Leal, MD, associate professor and director of the Thoracic Medical Oncology Program in the Department of Hematology and Medical Oncology at Emory University School of Medicine, discusses the latest advances in perioperative non–small cell lung cancer (NSCLC) treatment.

Neil Goldfarb, president and chief executive officer of the Greater Philadelphia Business Coalition on Health (GPBCH), previews the variety of themes and sessions at the upcoming GPBCH Annual Wellness Summit taking place September 10, 2024.

The HERCULES study of tolebrutinib is the first and only to show reduced confirmed disability progression at 6 months in nonrelapsing secondary progressive multiple sclerosis (MS).

Jason Romancik, MD, a board-certified hematologist at Emory Winship Cancer Institute, discusses the current treatment landscape in aggressive lymphoma and drivers of high care costs.

Twice-yearly inclisiran (Leqvio) monotherapy showed clinically meaningful and statistically significant LDL-C lowering in patients at low or moderate risk of atherosclerotic cardiovascular disease in the V-MONO study.

Although rare, clinicians should be familiar with the symptoms and management of immune checkpoint inhibitor (ICI)–related cardiovascular adverse effects or myocarditis.

While it can seem overwhelming or difficult to decide where to start addressing racial and ethnic disparities in health care, the key is to focus on a manageable area that can be built upon.

The disease-modifying treatment landscape has expanded in recent years, but access to the latest approved Duchenne muscular dystrophy (DMD) treatments can be a challenge for patients and providers, Aravindhan Veerapandiyan, MD, a pediatric neuromuscular specialist at Arkansas Children’s Hospital, said.

Treatment with bimekizumab showed consistent efficacy through 52 weeks in patients with psoriatic arthritis in a post hoc analysis of the BE OPTIMAL, BE COMPLETE, and BE VITAL trials.

Both cycling and home-based exercise training helped maintain gait and balance parameters in children with Duchenne muscular dystrophy (DMD), with cycling training also improving antero-posterior balance.

Demetria Smith-Graziani, MD, MPH, Emory University School of Medicine, explained biological and structural obstacles to equitable breast cancer outcomes and care across racial and ethnic groups.

A predictive tool considering disease duration, age at disease onset, age, and Expanded Disability Status Scale score estimated patients’ risk of transition to secondary progressive multiple sclerosis (MS).

Lumbar spine bone mineral density improved significantly and was maintained during long-term tumor necrosis factor inhibitor (TNFi) treatment for axial spondyloarthritis.

A codesigned online nutrition program could potentially fill a need for reliable and evidence-based nutrition information for patients with multiple sclerosis (MS).

Study results demonstrated significant correlations between fatigue and reductions in walking speed and mobility among patients with multiple sclerosis.

The identification of unique pulmonary fibrosis endotypes is an important step in the development of precision medicine approaches for the incurable condition.

The investigational therapy for heart failure (HF) with mildly reduced or preserved injection fraction met its primary end point in the phase 3 trial, Bayer announced.

Engaging with healthy lifestyle behaviors, including a healthy diet and physical activity, was associated with better outcomes among patients with multiple sclerosis (MS).

Aravindhan Veerapandiyan, MD, of the Division of Pediatric Neurology at the University of Arkansas for Medical Sciences, discussed the Duchenne muscular dystrophy (DMD) therapy landscape and barriers to treatment access.

Afami-cel, sold as Tecelra by Adaptimmune, is the first gene therapy to be approved for the rare form of cancer and the first FDA-approved T-cell receptor gene therapy.

As pharmacy benefit managers (PBMs) come under increased scrutiny from regulatory agencies, here are 5 things to know about their role in the health care system.